These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 24217844)

  • 1. Biological therapies in rheumatic diseases.
    Conti F; Ceccarelli F; Massaro L; Cipriano E; Di Franco M; Alessandri C; Spinelli FR; Scrivo R
    Clin Ter; 2013; 164(5):e413-28. PubMed ID: 24217844
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Off-label use of biological therapies in systemic diseases].
    Hachulla E
    Rev Med Interne; 2010 Dec; 31 Suppl 3():S307-14. PubMed ID: 21036424
    [No Abstract]   [Full Text] [Related]  

  • 3. [Introduction to biological drugs].
    Fernández-Cruz E; Alecsandru D; Rodríguez-Sainz C
    Actas Dermosifiliogr; 2008 Jul; 99 Suppl 4():2-6. PubMed ID: 19080985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Indications and efficacy of biologics in inflammatory arthritis].
    Combe B
    Bull Acad Natl Med; 2012 Oct; 196(7):1279-92; discussion 1293. PubMed ID: 23815014
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Biologic treatment of pediatric rheumatic diseases: are we spoilt for choice?
    van Royen-Kerkhof A; Vastert BS; Swart JF; Wulffraat NM
    Immunotherapy; 2014; 6(1):1-3. PubMed ID: 24341875
    [No Abstract]   [Full Text] [Related]  

  • 6. [Rheumatoid arthritis: current status of therapy].
    El Bahri DM; Meddeb N; Sellami S
    Tunis Med; 2007 Jan; 85(1):1-8. PubMed ID: 17424701
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The use of anti-tumour necrosis factor therapy in HIV-positive individuals with rheumatic disease.
    Cepeda EJ; Williams FM; Ishimori ML; Weisman MH; Reveille JD
    Ann Rheum Dis; 2008 May; 67(5):710-2. PubMed ID: 18079191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study.
    Heiberg MS; Koldingsnes W; Mikkelsen K; Rødevand E; Kaufmann C; Mowinckel P; Kvien TK
    Arthritis Rheum; 2008 Feb; 59(2):234-40. PubMed ID: 18240258
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incidence of influenza-like illness into a cohort of patients affected by chronic inflammatory rheumatism and treated with biological agents.
    Bello SL; Serafino L; Bonali C; Terlizzi N; Fanizza C; Anecchino C; Lapaldula G
    Reumatismo; 2012 Dec; 64(5):299-306. PubMed ID: 23256105
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serious infections associated with anticytokine therapies in the rheumatic diseases.
    Giles JT; Bathon JM
    J Intensive Care Med; 2004; 19(6):320-34. PubMed ID: 15523118
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistence of Staphylococcus aureus colonization among individuals with immune-mediated inflammatory diseases treated with TNF-α inhibitor therapy.
    Varley CD; Deodhar AA; Ehst BD; Bakke A; Blauvelt A; Vega R; Yamashita S; Winthrop KL
    Rheumatology (Oxford); 2014 Feb; 53(2):332-7. PubMed ID: 24173434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Problems encountered during anti-tumour necrosis factor therapy.
    Desai SB; Furst DE
    Best Pract Res Clin Rheumatol; 2006 Aug; 20(4):757-90. PubMed ID: 16979537
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoclonal antibody and intravenous immunoglobulin therapy for rheumatic diseases: rationale and mechanisms of action.
    Bayry J; Lacroix-Desmazes S; Kazatchkine MD; Kaveri SV
    Nat Clin Pract Rheumatol; 2007 May; 3(5):262-72. PubMed ID: 17471245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Innovative uses of tumor necrosis factor alpha inhibitors.
    Mazza J; Rossi A; Weinberg JM
    Dermatol Clin; 2010 Jul; 28(3):559-75. PubMed ID: 20510765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potential of tumor necrosis factor neutralization strategies in rheumatologic disorders other than rheumatoid arthritis.
    Stokes DG; Kremer JM
    Semin Arthritis Rheum; 2003 Aug; 33(1):1-18. PubMed ID: 12920692
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drug insight: different mechanisms of action of tumor necrosis factor antagonists-passive-aggressive behavior?
    Rigby WF
    Nat Clin Pract Rheumatol; 2007 Apr; 3(4):227-33. PubMed ID: 17396108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Proteins in rheumatology and clinical immunology].
    Villiger PM
    Ther Umsch; 2011 Nov; 68(11):603-9. PubMed ID: 22045522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease.
    Smith JR; Levinson RD; Holland GN; Jabs DA; Robinson MR; Whitcup SM; Rosenbaum JT
    Arthritis Rheum; 2001 Jun; 45(3):252-7. PubMed ID: 11409666
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009.
    Furst DE; Keystone EC; Fleischmann R; Mease P; Breedveld FC; Smolen JS; Kalden JR; Braun J; Bresnihan B; Burmester GR; De Benedetti F; Dörner T; Emery P; Gibofsky A; Kavanaugh A; Kirkham B; Schiff MH; Sieper J; Singer N; Van Riel PL; Weinblatt ME; Weisman MH; Winthrop K
    Ann Rheum Dis; 2010 Jan; 69 Suppl 1():i2-29. PubMed ID: 19995740
    [No Abstract]   [Full Text] [Related]  

  • 20. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents.
    Finckh A; Ciurea A; Brulhart L; Kyburz D; Möller B; Dehler S; Revaz S; Dudler J; Gabay C;
    Arthritis Rheum; 2007 May; 56(5):1417-23. PubMed ID: 17469098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.